New drug cocktail aims to stop rare blood cancer after transplant

NCT ID NCT07389616

Recruiting now Disease control Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether combining two drugs, cidabenamine and azacitidine, can stop high-risk peripheral T-cell lymphoma from progressing after a stem cell transplant. About 40 adults aged 18 to 70 will receive the drug combo as maintenance therapy. The goal is to see if it improves survival and keeps the cancer from coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cidabenamine and azacitidine
What this could lead to: If this works, it could offer a way to keep high-risk peripheral T-cell lymphoma from coming back after a stem cell transplant, potentially improving survival.
What could go wrong: This is a small, early-phase trial with only 40 participants and no comparison group, so results may not be conclusive. The drugs may cause side effects or fail to prevent relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL T-CELL LYMPHOMA

Contacts and locations

Locations

Shanghai General hospital,Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.